| Clinicopathological features |
IBC (N = 20) |
non-IBC (N = 20) |
P-value |
| Patients’ ages (years) |
| Mean |
49 |
50.2 |
|
| Range |
34-70 |
29-78 |
0.236 |
| Tumour stage |
| I |
0 (0%) |
0 (0%) |
|
| II |
0 (0%) |
6 (30%) |
|
| III |
0 (0%) |
13 (65%) |
|
| IV |
IVd20 (100%) |
IVb1 (5%) |
|
| Histological tumour gradea |
| I |
0 (0%) |
0 (0%) |
|
| II |
9 (45%) |
7 (35%) |
0.264 |
| III |
11 (55%) |
13 (65%) |
|
| Node status |
| N0 |
2 (10%) |
7 (35%) |
|
| N1 |
16 (80%) |
13 (65%) |
0,064 |
| N2 |
2 (10%) |
0 |
|
| N3 |
0 (0%) |
0 |
|
| Distant metastasis |
| M0 |
14 (70%) |
4 (20%) |
|
| M1 |
0 (0%) |
2 (10%) |
0,001 |
| Unknown |
6 (30%) |
14 (70%) |
|
| Oestrogen receptor |
| Positive |
3(15%) |
11 (55%) |
0.0018 |
| Negative |
17(85%) |
9 (35%) |
|
| HER2 amplification |
| Positive |
13 (65%) |
13 (65%) |
0.2 |
| Negative |
7 (35%) |
7 (35%) |
|
HER2: Human Epidermal Growth Factor Receptor 2; IBC: Inflammatory
207 Breast Cancer |
|
